Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol. 1998;91(3):349–354. 9491858
   PubMed Web of Science ®Google Scholar
• Lee TS, Jung JY, Kim JW, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol. 2007;104(1):52–57. doi:10.1016/j.ygyno.2006.07.00316887175
   PubMed Web of Science ®Google Scholar
• Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83(2):388–393. doi:10.1006/gyno.2001.643411606102
   PubMed Web of Science ®Google Scholar
• Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64(3):417–420. 6462572
   PubMed Web of Science ®Google Scholar
• Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575–580. doi:10.1097/01.AOG.0000154151.14516.f715738027
   PubMed Web of Science ®Google Scholar
• Gressel G, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015;131(3):234–239. doi:10.1016/j.ijgo.2015.06.03126384790
   PubMed Web of Science ®Google Scholar
• Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. J Obstet Gynaecol. 2011;31(1):13–17. doi:10.3109/01443615.2010.53224921280986
   PubMedGoogle Scholar
• Creasman W, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60(8 Suppl):2035–2041. 3652025
   PubMed Web of Science ®Google Scholar
• Boronow R, Morrow CP, Creasman WT, et al. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984;63(6):825–832. 6728365
   PubMed Web of Science ®Google Scholar
• Park J-Y, Kim D-Y, Kim J-H, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868–874. doi:10.1016/j.ejca.2012.09.01723072814
   PubMed Web of Science ®Google Scholar
• Kudesia R, Singer T, Caputo TA, et al. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol. 2014;210(3):255.e1–4. doi:10.1016/j.ajog.2013.11.001
   PubMed Web of Science ®Google Scholar
• Pronin SM, Novikova OV, Andreeva JY, Novikova EG. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Int J Gynecol Cancer. 2015;25(6):1010–1014. doi:10.1097/IGC.000000000000046725950126
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Jobo T, Takei Y, et al. Fertility-sparing treatment using medroxyprogesterone acetate for endometrial carcinoma. Oncol Lett. 2012;3(5):1002–1006. doi:10.3892/ol.2012.60222783380
   PubMed Web of Science ®Google Scholar
• Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101(3):785–794. doi:10.1016/j.fertnstert.2013.11.02824388202
   PubMed Web of Science ®Google Scholar
• Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25(19):2798–2803. doi:10.1200/JCO.2006.08.834417602085
   PubMed Web of Science ®Google Scholar
• Kim MK, Yoon BS, Park H, et al. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer. 2011;21(4):673–677. doi:10.1111/IGC.0b013e3181fd9a0621546871
   PubMed Web of Science ®Google Scholar
• Tamauchi S, Kajiyama H, Utsumi F, et al. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer. J Obstet Gynaecol Res. 2018;44(1):151–156. doi:10.1111/jog.1347329121428
   PubMed Web of Science ®Google Scholar
• Fukui Y, Taguchi A, Adachi K, et al. Polycystic ovarian morphology may be a positive prognostic factor in patients with endometrial cancer who achieved complete remission after fertility-sparing therapy with progestin. Asian Pac J Cancer Prev. 2017;18(11):3111–3116. doi:10.22034/APJCP.2017.18.11.311129172287
   PubMedGoogle Scholar
• Hwang JY, Kim DH, Bae HS, et al. Combined oral medroxyprogesterone/levonorgestrel-intrauterine system treatment for women with grade 2 stage IA endometrial cancer. Int J Gynecol Cancer. 2017;27(4):738–742. doi:10.1097/IGC.000000000000092728346240
   PubMed Web of Science ®Google Scholar
• Park J-Y, Seong SJ, Kim T-J, Kim JW, Bae D-S, Nam J-H. Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol. 2017;146(1):39–43. doi:10.1016/j.ygyno.2017.05.00228526167
   PubMed Web of Science ®Google Scholar
• Kim SR, van der Zanden C, Ikiz H, Kuzelijevic B, Havelock J, Kwon JS. Fertility-sparing management using progestin for young women with endometrial cancer from a population-based study. J Obstet Gynaecol Can. 2018;40(3):328–333. doi:10.1016/j.jogc.2017.06.03728986185
   PubMed Web of Science ®Google Scholar
• Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016;132(1):34–38. doi:10.1016/j.ijgo.2015.06.04626493012
   PubMed Web of Science ®Google Scholar
• Baek JS, Lee WH, Kang WD, Kim SM. Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci. 2016;59(1):24–31. doi:10.5468/ogs.2016.59.1.2426866032
   PubMedGoogle Scholar
• Zhou R, Yang Y, Lu Q, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients. Gynecol Oncol. 2015;139(3):424–428. doi:10.1016/j.ygyno.2015.09.07826428941
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27(2):262–266. doi:10.1093/annonc/mdv53926578736
   PubMed Web of Science ®Google Scholar
• Simpson AN, Feigenberg T, Clarke BA, et al. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin. Gynecol Oncol. 2014;133(2):229–233. doi:10.1016/j.ygyno.2014.02.02024561246
   PubMed Web of Science ®Google Scholar
• Gonthier C, Walker F, Luton D, Yazbeck C, Madelenat P, Koskas M. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer. Gynecol Oncol. 2014;133(1):33–37. doi:10.1016/j.ygyno.2013.11.00724680589
   PubMed Web of Science ®Google Scholar
• Jafari Shobeiri, M, Gharabaghi, PM, Esmaeili, H, et al. Fertility sparing treatment in young patients with early endometrial adenocarcinoma. Pak J Med Sci. 2013;29(2):651–655.
   PubMed Web of Science ®Google Scholar
• Koskas M, Azria E, Walker F, Luton D, Madelenat P, Yazbeck C. Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility. Anticancer Res. 2012;32(3):1037–1043. 22399629
   PubMed Web of Science ®Google Scholar
• Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view. Eur Rev Med Pharmacol Sci. 2012;16(14):1934–1937. 23242719
   PubMed Web of Science ®Google Scholar
• Perri T, Korach J, Gotlieb WH, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer. 2011;21(1):72–78. doi:10.1097/IGC.0b013e31820003de21178572
   PubMed Web of Science ®Google Scholar
• Park H, Seok JM, Yoon BS, et al. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet. 2012;285(2):473–478. doi:10.1007/s00404-011-1959-x21706284
   PubMed Web of Science ®Google Scholar
• Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22(3):643–649. doi:10.1093/annonc/mdq46320876910
   PubMed Web of Science ®Google Scholar
• Yu M, Yang J-X, Wu M, Lang J-H, Huo Z, Shen K. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril. 2009;92(6):2122–2124. doi:10.1016/j.fertnstert.2009.06.01319591991
   PubMed Web of Science ®Google Scholar
• Han AR, Kwon Y-S, Kim DY, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19(1):147–151. doi:10.1111/IGC.0b013e31819960ba19258957
   PubMed Web of Science ®Google Scholar
• Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19(6):1068–1073. doi:10.1111/IGC.0b013e3181aae1fb19820370
   PubMed Web of Science ®Google Scholar
• Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG. 2009;116(1):114–118. doi:10.1111/j.1471-0528.2008.02024.x19087082
   PubMed Web of Science ®Google Scholar
• Yamazawa K, Hirai M, Fujito A, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22(7):1953–1958. doi:10.1093/humrep/dem08817449880
   PubMed Web of Science ®Google Scholar
• Yang Y-C, Wu -C-C, Chen C-P, Chang C-L, Wang K-L. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol. 2005;99(2):287–293. doi:10.1016/j.ygyno.2005.06.01816051341
   PubMed Web of Science ®Google Scholar
• Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006;21(4):1070–1075. doi:10.1093/humrep/dei43416361282
   PubMed Web of Science ®Google Scholar
• Gotlieb W. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102(4):718–725. 14551001
   PubMed Web of Science ®Google Scholar
• Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266 e1–12. doi:10.1016/j.ajog.2012.08.01123021687
   PubMed Web of Science ®Google Scholar
• Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–482. doi:10.1016/j.ygyno.2012.01.00322245711
   PubMed Web of Science ®Google Scholar
• Minig L, Franchi D, Valero de Bernabé J, Sideri M. Controversies of the hormonal conservative treatment of endometrial cancer. Gynecol Obstet Invest. 2013;75(3):145–151. doi:10.1159/00034989123548769
   PubMed Web of Science ®Google Scholar
• Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist. 2015;20(3):270–278. doi:10.1634/theoncologist.2013-044525673106
   PubMed Web of Science ®Google Scholar
• Erkanli S, Ayhan A. Fertility-Sparing Therapy in Young Women With Endometrial Cancer. Intl J Gynecol Cancer. 2010;20(7):1170–1187.
   PubMed Web of Science ®Google Scholar
• Feichtinger M, Rodriguez-Wallberg KA. Fertility preservation in women with cervical, endometrial or ovarian cancers. Gynecol Oncol Res Pract. 2016;3:8. doi:10.1186/s40661-016-0029-227468354
   PubMedGoogle Scholar
• Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer. 2018;28(2):385–393. doi:10.1097/IGC.000000000000116429266019
   PubMed Web of Science ®Google Scholar
• Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. doi:10.1136/bmj.39367.495995.AE17986716
   PubMed Web of Science ®Google Scholar
• Bessonova L, Marshall SF, Ziogas A, et al. The association of body mass index with mortality in the California Teachers Study. Int J Cancer. 2011;129(10):2492–2501. doi:10.1002/ijc.2590521207419
   PubMed Web of Science ®Google Scholar
• Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518–525. doi:10.1016/j.ajog.2011.05.04221802066
   PubMed Web of Science ®Google Scholar
• Courneya K, Karvinen KH, Campbell KL, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005;97(2):422–430. doi:10.1016/j.ygyno.2005.01.00715863140
   PubMed Web of Science ®Google Scholar
• Arem H, Irwin ML. Obesity and endometrial cancer survival: a systematic review. Int J Obes (Lond). 2013;37(5):634–639. doi:10.1038/ijo.2012.9422710929
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obes Facts. 2009;2(1):26–35. doi:10.1159/00019497120054201
   PubMed Web of Science ®Google Scholar
• Piltonen TT. Polycystic ovary syndrome: Endometrial markers. Best Pract Res Clin Obstet Gynaecol. 2016;37:66–79. doi:10.1016/j.bpobgyn.2016.03.00827156350
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–861. doi:10.1056/NEJM1995092833313077651477
   PubMed Web of Science ®Google Scholar
• Okamura Y, Saito F, Takaishi K, et al. Polycystic ovary syndrome: early diagnosis and intervention are necessary for fertility preservation in young women with endometrial cancer under 35 years of age. Reprod Med Biol. 2017;16(1):67–71. doi:10.1002/rmb2.1201229259453
   PubMedGoogle Scholar
• Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000;65(10–11):629–636. 11108869
   PubMed Web of Science ®Google Scholar
• Schindler A, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–S16. 14670641
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Eriksen P, Christensen M. Plasma concentrations of megestrol acetate and medroxyprogesterone acetate after single oral administration to healthy subjects. J Pharm Biomed Anal. 1983;1(2):153–162. 16867813
   PubMedGoogle Scholar
• Schmeler, KM, Soliman, PT, Sun, CC, et al. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005;99(2):388–392. 16051336
   PubMed Web of Science ®Google Scholar
• Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol. 2009;25(10):683–691. doi:10.1080/0951359090273373319562604
   PubMed Web of Science ®Google Scholar
• Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89(8):1765–1772. 11042572
   PubMed Web of Science ®Google Scholar
• Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991;77(6):954–956. 2030877
   PubMed Web of Science ®Google Scholar
• Kim DH, Seong SJ, Kim MK, et al. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system. J Gynecol Oncol. 2017;28(1):e1. doi:10.3802/jgo.2017.28.e127670255
   PubMed Web of Science ®Google Scholar